secwatch.observer — SEC 8-K summary
======================================

Issuer:     DELCATH SYSTEMS, INC. (DCTH)
CIK:        0000872912
Form:       8-K
Filed at:   2026-08-06T12:10:00+00:00
Accession:  0001628280-26-053902
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Delcath Q2 revenue $29.1M, up 20% YoY; raises FY 2026 revenue guidance to $104-108M
--------------------------------------------------------------------------------

- Total revenue $29.1M (Q2 2026) vs $24.2M (Q2 2025); HEPZATO KIT $27.1M, CHEMOSAT $2.0M.
- Net income $2.7M (flat YoY); non-GAAP adjusted EBITDA $7.6M vs $9.8M prior year.
- Cash and investments $95.9M, no debt as of June 30, 2026.
- FY 2026 revenue guidance raised to $104-108M (≥28% HEPZATO volume growth); gross margins 86-89%.
- 31 active treatment centers; HEPZATO volume grew ~30% YoY in Q2.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/872912/000162828026053902/0001628280-26-053902-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/872912/000162828026053902/dcth-20260806.htm
  HTML page:      https://secwatch.observer/filing/0001628280-26-053902

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer